Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from CytomX Therapeutics ( (CTMX) ) is now available.
On March 17, 2026, CytomX Therapeutics, Inc. entered into an underwriting agreement with a syndicate of banks to offer 45,990,567 shares of common stock at $5.30 per share and pre-funded warrants to purchase 1,179,245 shares at $5.29999 each. The agreement also grants underwriters a 30-day option to buy up to 7,075,471 additional shares at the public offering price, with the deal conducted under an effective shelf registration.
The offering closed on March 19, 2026, resulting in the sale and issuance of all 45,990,567 shares and the pre-funded warrants, from which CytomX expects to raise approximately $234.4 million in net proceeds after fees and expenses. The company plans to use these funds to advance development of Varseta-M and other pipeline programs and to support general corporate purposes and working capital, bolstering its funding base for ongoing clinical and operational activities.
The most recent analyst rating on (CTMX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.
Spark’s Take on CTMX Stock
According to Spark, TipRanks’ AI Analyst, CTMX is a Neutral.
CTMX’s score is held down primarily by weak financial fundamentals—especially sustained negative operating/free cash flow and volatile profitability—alongside soft technical signals with the stock trading below key moving averages. The latest earnings call provides a meaningful offset via positive clinical progress and a stated funding runway into at least Q2 2027, but valuation inputs are not sufficiently usable (P/E shown as 0.000; no dividend yield) to materially improve the overall score.
To see Spark’s full report on CTMX stock, click here.
More about CytomX Therapeutics
CytomX Therapeutics, Inc. is a biopharmaceutical company focused on developing novel oncology therapies, including its lead program Varseta-M and other pipeline drug candidates. The company targets cancer indications, aiming to leverage its pipeline to strengthen its position in the competitive cancer therapeutics market and support ongoing research and development activities.
Average Trading Volume: 5,905,209
Technical Sentiment Signal: Buy
Current Market Cap: $748.8M
Find detailed analytics on CTMX stock on TipRanks’ Stock Analysis page.